At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
In Brief
A Phase 4 clinical trial evaluating Quetiapine 50 MG Extended Release Oral Tablet, Quetiapine Fumarate XR 150-300 mg, and 1 other intervention for Depressive Disorder, Major. Completed, enrolled 1,790 participants.
Detailed Summary
In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis. Hypothesis 1: Is low-dose quetiapine (50 mg/day) more effective for patients with depression who have insomnia at treatment baseline? (Stated differently: is low-dose quetiapine 50 mg/day effective as monotherapy for patients with depression regardless of whether or not they have insomnia at baseline?). Hypothesis 2: Is high-dose quetiapine (150 - 300 mg/day) more effective for patients presenting with melancholic depression at treatment baseline?
Study Details
Timeline
Interventions
OD
Dose ranged from 150 to 300mg, XR preparation, OD
Placebo